Compare NNNN & CPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNNN | CPF |
|---|---|---|
| Founded | 2021 | 1954 |
| Country | Germany | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 997.1M |
| IPO Year | N/A | 2011 |
| Metric | NNNN | CPF |
|---|---|---|
| Price | $11.49 | $37.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.00 |
| AVG Volume (30 Days) | 43.0K | ★ 152.0K |
| Earning Date | 04-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | N/A | ★ 45.18 |
| EPS | N/A | ★ 0.78 |
| Revenue | N/A | ★ $51,817,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.62 |
| P/E Ratio | $446.57 | ★ $48.99 |
| Revenue Growth | N/A | ★ 33.81 |
| 52 Week Low | $10.50 | $25.62 |
| 52 Week High | $55.65 | $39.20 |
| Indicator | NNNN | CPF |
|---|---|---|
| Relative Strength Index (RSI) | 26.28 | 56.74 |
| Support Level | $10.50 | $33.33 |
| Resistance Level | $30.21 | N/A |
| Average True Range (ATR) | 1.95 | 0.95 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 4.22 | 58.15 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services. It operates in single segment which is Banking operations.